Trial Profile
A clinical phase II study assessing the safety and efficacy of readministration of bendamustine monotherapy or bendamustine/rituximab for relapsed low grade B cell non-Hodgkin lymphoma or mantle cell lymphoma patients previously treated with bendamustine containing chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Dec 2020
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 15 Dec 2020 Status changed from active, no longer recruiting to completed.
- 18 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 08 Jul 2013 New trial record